Literature DB >> 9371352

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

C M Douglas1, J A D'Ippolito, G J Shei, M Meinz, J Onishi, J A Marrinan, W Li, G K Abruzzo, A Flattery, K Bartizal, A Mitchell, M B Kurtz.   

Abstract

Pneumocandins and echinocandins are fungicidal antibiotics, currently in clinical development, that inhibit 1,3-beta-D-glucan synthase (GS) in several human fungal pathogens. We have identified a gene from the diploid organism Candida albicans that encodes a target of these inhibitors. A 2.1-kb portion of this gene, designated CaFKS1, has significant homology to the Saccharomyces cerevisiae FKS1 and FKS2 genes, which encode partially functionally redundant subunits of GS. To evaluate the role of CaFkslp in susceptibility to echinocandins, we disrupted CaFKS1 on one homolog each of the spontaneous pneumocandin-resistant C. albicans mutants CAI4R1, NR2, NR3, and NR4. These mutants had been selected previously on agar plates containing the pneumocandin L-733,560. The clones derived from this transformation were either resistant (Ech[r]) or fully sensitive (Ech[s]) to inhibition by L-733,560 in both liquid broth microdilution and in vitro GS assays. The site of plasmid insertion in the transformants was mapped by Southern blot analysis, using restriction site polymorphisms in the CaFKS1 gene to distinguish between the two alleles (designated CaFKS1h and CaFKS1b). For strains CAI4R1 and NR2, the CaFKS1b allele was disrupted in each Ech(r) transformant; for strain NR4, CaFKS1h was disrupted in each Ech(r) transformant. We conclude that (i) strains CAI4R1, NR2, and NR4 are heterozygous for a dominant or semidominant pneumocandin resistance mutation at CaFKS1, (ii) drug resistance mutations can occur in either CaFKS1 allele, and (iii) CaFks1p is a target of the echinocandins. For transformants of strain NR3, all the clones we analyzed were uniformly Ech(r), and only the CaFKS1h allele, either in disrupted or wild-type form, was detected on genomic Southern blots. We believe gene conversion at the CaFKS1 locus may have produced two Cafks1h alleles that each contain an Ech(r) mutation. Transformants derived from the mutants were analyzed for susceptibility to pneumocandin treatment in a mouse model of disseminated candidiasis. Strains heterozygous for the resistant allele (i.e., C. albicans CAI4R1, NR2, and NR4) were moderately resistant to treatment, while strains without a functional Ech(s) allele (i.e., strain NR3 and derivatives of strain CAI4R1 with the disruption plasmid integrated in the Ech[s] allele) displayed strong in vivo echinocandin resistance. Finally, we were unable to inactivate both alleles at CaFKS1 by two-step integrative disruption, suggesting that CaFks1p is likely to be an essential protein in C. albicans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371352      PMCID: PMC164147     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  A simple and efficient procedure for transformation of yeasts.

Authors:  R Elble
Journal:  Biotechniques       Date:  1992-07       Impact factor: 1.993

2.  Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP).

Authors:  J M Balkovec; R M Black; M L Hammond; J V Heck; R A Zambias; G Abruzzo; K Bartizal; H Kropp; C Trainor; R E Schwartz
Journal:  J Med Chem       Date:  1992-01       Impact factor: 7.446

3.  New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites.

Authors:  R D Gietz; A Sugino
Journal:  Gene       Date:  1988-12-30       Impact factor: 3.688

4.  Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Authors:  F A Bouffard; R A Zambias; J F Dropinski; J M Balkovec; M L Hammond; G K Abruzzo; K F Bartizal; J A Marrinan; M B Kurtz; D C McFadden
Journal:  J Med Chem       Date:  1994-01-21       Impact factor: 7.446

5.  Isogenic strain construction and gene mapping in Candida albicans.

Authors:  W A Fonzi; M Y Irwin
Journal:  Genetics       Date:  1993-07       Impact factor: 4.562

6.  A rapid, efficient method for isolating DNA from yeast.

Authors:  C Holm; D W Meeks-Wagner; W L Fangman; D Botstein
Journal:  Gene       Date:  1986       Impact factor: 3.688

7.  Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein.

Authors:  R Kelly; E Register; M J Hsu; M Kurtz; J Nielsen
Journal:  J Bacteriol       Date:  1996-08       Impact factor: 3.490

8.  Classification of fungal chitin synthases.

Authors:  A R Bowen; J L Chen-Wu; M Momany; R Young; P J Szaniszlo; P W Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

9.  In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Authors:  K Bartizal; G Abruzzo; C Trainor; D Krupa; K Nollstadt; D Schmatz; R Schwartz; M Hammond; J Balkovec; F Vanmiddlesworth
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  Cloning of the chitin synthase 3 gene from Candida albicans and its expression during yeast-hyphal transition.

Authors:  M Sudoh; S Nagahashi; M Doi; A Ohta; M Takagi; M Arisawa
Journal:  Mol Gen Genet       Date:  1993-11
View more
  120 in total

1.  In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; J Lowther; A Bryskier; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae.

Authors:  Petros Ioannou; Aggeliki Andrianaki; Tonia Akoumianaki; Irene Kyrmizi; Nathaniel Albert; David Perlin; George Samonis; Dimitrios P Kontoyiannis; Georgios Chamilos
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 4.  Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.

Authors:  Lesley J Scott
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

5.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Elena Alvarez; Fernando Baquero; Ramón Cisterna; Joaquina Gil; Estrella Martín-Mazuelos; Carmen Rubio; Aurora Sánchez-Sousa; Carmen Serrano
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Coccidioides posadasii contains a single 1,3-beta-glucan synthase gene that appears to be essential for growth.

Authors:  Ellen M Kellner; Kris I Orsborn; Erin M Siegel; M Alejandra Mandel; Marc J Orbach; John N Galgiani
Journal:  Eukaryot Cell       Date:  2005-01

8.  Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Authors:  Morgan Hakki; Janet F Staab; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

9.  Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.

Authors:  Mette D Jacobsen; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

10.  Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.

Authors:  M C Cruz; A L Goldstein; J Blankenship; M Del Poeta; J R Perfect; J H McCusker; Y L Bennani; M E Cardenas; J Heitman
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.